Table 9.
HDAC6 Inhibitors in Clinical Trials in Cancer. Clinical studies include four phases. Phase I is performed on healthy volunteers to determine the maximum tolerated dose in humans. Phase II is performed on a limited patient population to determine the optimal dosage. Phase III is performed on several thousand patients and will demonstrate the therapeutic value of the drug and assess its benefit/risk. Phase IV is performed once the drug is marketed and allows to better characterize its adverse effects.
| HDAC6 Inhibitor | Clinical Trial Identification | Phase of the Clinical Trial | Pathology |
|---|---|---|---|
| ACY-241 | NCT02400242 | Ia/Ib | Multiple myeloma |
| NCT02935790 | Ib | Stage III and IV unresectable melanoma | |
| NCT02551185 | Ib | Advanced solid tumors | |
| NCT02635061 | Ib | Non-resectable non-small cell lung cancer | |
| ACY-1215 | NCT02632071 | Ib | Unresectable or metastatic breast cancer |
| NCT02787369 | Ib | Relapsed chronic lymphocytic leukemia | |
| NCT02091063 | Ib/II | Relapsed or refractory lymphoid malignancies | |
| NCT01997840 | Ib/II | Recurrent and refractory multiple myeloma | |
| NCT01583283 | I/II | Multiple myeloma recurrent or recurrent and refractory | |
| NCT02189343 | Ib | Recurrent and refractory multiple myeloma | |
| NCT01323751 | I/II | Multiple myeloma recurrent or recurrent and refractory | |
| NCT02856568 | Ib | Unresectable or metastatic cholangiocarcinoma | |
| NCT02661815 | Ib | Ovarian cancer, primary peritoneal cancer or platinum-resistant fallopian tubes |